James V. Cassella, Chief Development Officer at CONCERT PHARMACEUTICALS, INC. (CNCE), sold 3,762 shares at $3.09 ($12K) on 2022-02-14, disclosed to the SEC on 2022-02-16.
Scheduled sale ($12k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CNCE | SELL | 2023-01-09 | $21K | — | Filing → |
| CNCE | SELL | 2022-01-07 | $9K | — | Filing → |
| CNCE | SELL | 2021-08-17 | $27K | — | Filing → |